Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert
{"title":"Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study.","authors":"Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert","doi":"10.2217/cns-2021-0007","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. <b>Patients & methods:</b> US Oncology Network data were analyzed for patients receiving first-line (1L) treatment for GBM. <b>Results:</b> Most patients received 1L radiation with temozolomide. Unadjusted median overall survival (OS) was higher in tested versus untested (median:18.1 vs 11.8 months) and in methylated versus unmethylated (median: 25.5 vs 12.4 months). Untested status, unmethylated MGMT and older age were associated with reduced OS and longer 1L treatment with increased OS. Similar findings were observed for progression-free survival. Utilization was similar between cohorts. <b>Conclusion:</b> In community oncology practices, MGMT methylation and testing were predictive of better survival in GBM.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/e0/cns-10-76.PMC8461754.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2021-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3
Abstract
Aim: Investigate real-world outcomes and healthcare utilization of patients with glioblastoma multiforme (GBM) related to O6-methylguanine DNA methyltransferase (MGMT) promoter testing and methylation. Patients & methods: US Oncology Network data were analyzed for patients receiving first-line (1L) treatment for GBM. Results: Most patients received 1L radiation with temozolomide. Unadjusted median overall survival (OS) was higher in tested versus untested (median:18.1 vs 11.8 months) and in methylated versus unmethylated (median: 25.5 vs 12.4 months). Untested status, unmethylated MGMT and older age were associated with reduced OS and longer 1L treatment with increased OS. Similar findings were observed for progression-free survival. Utilization was similar between cohorts. Conclusion: In community oncology practices, MGMT methylation and testing were predictive of better survival in GBM.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
